WHO ICTRP trial
The effect of usual dose rosuvastatin plus ezetimibe versus high-dose…
KCT0003092 · Clinical Research Information Service (CRIS) · Recruiting
Key facts
| Trial ID | KCT0003092 |
|---|---|
| Public title | The effect of usual dose rosuvastatin plus ezetimibe versus high-dose rosuvastatin on coronary atherosclerotic plaque |
| Scientific title | The effect of usual dose rosuvastatin plus ezetimibe versus high-dose rosuvastatin on coronary atherosclerotic plaque: A randomized controlled trial |
| Primary sponsor | Samsung Medical Center |
| Registry | Clinical Research Information Service (CRIS) |
| Recruitment status | Recruiting |
| Study type | Interventional Study |
| Phase | Not applicable |
| Countries | Korea, Republic of |
| Conditions | Diseases of the circulatory system |
| Interventions | Drug : Patients who have moderate stenosis (30-70%) in coronary artery and deferred to medical treatment by intracoronary physiologic or radiologic test with eligibility for inclusion and exclusion criteria, will be randomly assigned to… |
| Registration date | Aug 16, 2018 |
| Target size | 280 |
| Secondary IDs | NCT03169985 |
| Registry page | cris.nih.go.kr |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: